174 related articles for article (PubMed ID: 35804932)
1. Knockdown of 15-bp Deletion-Type v-raf Murine Sarcoma Viral Oncogene Homolog B1 mRNA in Pancreatic Ductal Adenocarcinoma Cells Repressed Cell Growth In Vitro and Tumor Volume In Vivo.
Song J; Kobayashi Y; Asano Y; Sato A; Taniguchi H; Ui-Tei K
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804932
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report.
Shin JE; An HJ; Park HS; Kim H; Shim BY
Front Oncol; 2022; 12():976450. PubMed ID: 36505826
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.
Chen SH; Zhang Y; Van Horn RD; Yin T; Buchanan S; Yadav V; Mochalkin I; Wong SS; Yue YG; Huber L; Conti I; Henry JR; Starling JJ; Plowman GD; Peng SB
Cancer Discov; 2016 Mar; 6(3):300-15. PubMed ID: 26732095
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of KRAS signaling in pancreatic cancer is not associated with
Lemstrova R; Brynychova V; Hughes DJ; Hlavac V; Dvorak P; Doherty JE; Murray HA; Crockard M; Oliverius M; Hlavsa J; Honsova E; Mazanec J; Kala Z; Lovecek M; Havlik R; Ehrmann J; Strouhal O; Soucek P; Melichar B; Mohelnikova-Duchonova B
Oncol Lett; 2017 Nov; 14(5):5980-5988. PubMed ID: 29113235
[TBL] [Abstract][Full Text] [Related]
5. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic
Ye Q; Srivastava P; Al-Kuwari N; Chen X
Neural Regen Res; 2023 Jul; 18(7):1613-1622. PubMed ID: 36571370
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
[TBL] [Abstract][Full Text] [Related]
9. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
10. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
[TBL] [Abstract][Full Text] [Related]
11. Eicosapentaenoic Acid Inhibits
Chiu CF; Hsu MI; Yeh HY; Park JM; Shen YS; Tung TH; Huang JJ; Wu HT; Huang SY
Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33801246
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Brahma expression by the mitogen-activated protein kinase/extracellular signal regulated kinase pathway is associated with changes in melanoma proliferation.
Mehrotra A; Saladi SV; Trivedi AR; Aras S; Qi H; Jayanthy A; Setaluri V; de la Serna IL
Arch Biochem Biophys; 2014 Dec; 563():125-35. PubMed ID: 25026375
[TBL] [Abstract][Full Text] [Related]
13. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
14. BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay.
Tatsuno M; Shioda Y; Iwafuchi H; Yamazaki S; Iijima K; Takahashi C; Ono H; Uchida K; Okamura O; Matubayashi M; Okuyama T; Matsumoto K; Yoshioka T; Nakazawa A
Diagn Pathol; 2016 Apr; 11():39. PubMed ID: 27094161
[TBL] [Abstract][Full Text] [Related]
15. Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer.
Yokota T; Shibata N; Ura T; Takahari D; Shitara K; Muro K; Yatabe Y
Transl Res; 2010 Aug; 156(2):98-105. PubMed ID: 20627194
[TBL] [Abstract][Full Text] [Related]
16. Identification of targetable BRAF ΔN486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a
Wrzeszczynski KO; Rahman S; Frank MO; Arora K; Shah M; Geiger H; Felice V; Manaa D; Dikoglu E; Khaira D; Chimpiri AR; Michelini VV; Jobanputra V; Darnell RB; Powers S; Choi M
Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31519698
[TBL] [Abstract][Full Text] [Related]
17. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
[TBL] [Abstract][Full Text] [Related]
18. V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) as a prognostic biomarker of poor outcomes in esophageal cancer patients.
Kuerbanjiang A; Maimaituerxun M; Zhang Y; Li Y; Cui G; Abuduhabaier A; Aierken A; Miranbieke B; Anzaer M; Maimaiti Y
BMC Gastroenterol; 2021 Feb; 21(1):86. PubMed ID: 33622273
[TBL] [Abstract][Full Text] [Related]
19. Lung Cancer Driven by BRAF
Huo KG; Notsuda H; Fang Z; Liu NF; Gebregiworgis T; Li Q; Pham NA; Li M; Liu N; Shepherd FA; Marshall CB; Ikura M; Moghal N; Tsao MS
J Thorac Oncol; 2022 Feb; 17(2):277-288. PubMed ID: 34648945
[TBL] [Abstract][Full Text] [Related]
20. Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients.
Yashima H; Shimizu K; Araki T; Aomori T; Ohtaki Y; Nagashima T; Enokida Y; Atsumi J; Nakamura T; Takeyoshi I; Yamamoto K
Mol Clin Oncol; 2014 Sep; 2(5):714-718. PubMed ID: 25054035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
